An approach to trial design and analysis in the era of nonproportional hazards of the treatment effect
 Patrick Royston^{1}Email author and
 Mahesh KB Parmar^{1}
DOI: 10.1186/1745621515314
© Royston and Parmar; licensee BioMed Central Ltd. 2014
Received: 17 September 2013
Accepted: 17 July 2014
Published: 7 August 2014
Abstract
Background
Most randomized controlled trials with a timetoevent outcome are designed and analysed under the proportional hazards assumption, with a target hazard ratio for the treatment effect in mind. However, the hazards may be nonproportional. We address how to design a trial under such conditions, and how to analyse the results.
Methods
We propose to extend the usual approach, a logrank test, to also include the GrambschTherneau test of proportional hazards. We test the resulting composite null hypothesis using a joint test for the hazard ratio and for timedependent behaviour of the hazard ratio. We compute the power and sample size for the logrank test under proportional hazards, and from that we compute the power of the joint test. For the estimation of relevant quantities from the trial data, various models could be used; we advocate adopting a prespecified flexible parametric survival model that supports timedependent behaviour of the hazard ratio.
Results
We present the mathematics for calculating the power and sample size for the joint test. We illustrate the methodology in real data from two randomized trials, one in ovarian cancer and the other in treating cellulitis. We show selected estimates and their uncertainty derived from the advocated flexible parametric model. We demonstrate in a small simulation study that when a treatment effect either increases or decreases over time, the joint test can outperform the logrank test in the presence of both patterns of nonproportional hazards.
Conclusions
Those designing and analysing trials in the era of nonproportional hazards need to acknowledge that a more complex type of treatment effect is becoming more common. Our method for the design of the trial retains the tools familiar in the standard methodology based on the logrank test, and extends it to incorporate a joint test of the null hypothesis with power against nonproportional hazards. For the analysis of trial data, we propose the use of a prespecified flexible parametric model that can represent a timedependent hazard ratio if one is present.
Keywords
Timetoevent data Randomized controlled trials Hazard ratio Nonproportional hazards Logrank test GrambschTherneau test Flexible parametric modelBackground
Most randomized controlled trials (RCTs) with a timetoevent outcome are designed and analysed under the proportional hazards assumption, with a target hazard ratio (HR) for the treatment effect in mind. However, the hazards may be nonproportional (nonPH). If so, questions arise as to how best to design the trial and analyse the results.
We believe that there may be two reasons that nonproportional hazards are being detected more frequently nowadays. First, phase III trials are generally much larger today, giving more power in any given situation to detect nonproportional hazards. Second, with the biological revolution there are many new therapies being evaluated, having different modes of action. For example, monoclonal antibodies have been evaluated for treating many different types of cancer. They are given for a defined period of time (often one or two years) and then stopped. It is entirely plausible that the effect of the intervention might persist during the treatment period but then diminish gradually afterwards. Such behaviour, which in fact is what has been seen in the examples given above, would lead to nonproportional hazards.
Typically, the sample size calculation for such a trial utilizes some form of logrank test. An estimate of the HR with a confidence interval (CI) is often obtained from a Cox model with treatment as the only covariate. If nonPH is present, the HR is actually timedependent and the estimated HR that is obtained is some type of average over the event times [1].
An alternative design approach is to alter the test used to analyse the data by adding a test for a possible timedependent treatment effect. Such a joint test may have more power than the logrank test when certain patterns of nonPH are present. To obtain the same power as for the logrank test under PH, an increase in the sample size is needed, or the target power under PH may be reduced, or the significance level of the test may be relaxed. We call a test of this type a ‘joint test’. We envisage a scenario in which we prespecify a more robust test that has power in the presence of nonPH. Once we have identified a ‘signal’, we can try to better understand its nature by further analysis of the data, as outlined in principle in the next paragraph.
Allied to the joint test, we propose the use of a joint model, which also incorporates a possible timedependent treatment effect. Presentation of results of a joint model may include KaplanMeier survival curves and a prespecified modelbased estimate of the treatment effect. This may be the estimate of the HR (with CI) at particular time points, or indeed, because of the timedependent nature of the results, other potentially more informative and clinically relevant quantities, such as differences in survival curves and in restricted mean survival times between arms [2].
The structure of the paper is as follows. In the Methods section, we motivate and describe the joint test of the HR and nonPH that we propose. We show how to repower the logrank test under PH to achieve the power desired for the joint test. We discuss the analysis of trial data and make a case for estimating quantities of interest, particularly those with a timedependent perspective, using a flexible parametric survival model as the joint model. We deal with the important issue of prespecifying the analysis in the protocol and statistical analysis plan. In the Results section, we give some numerical examples showing the implications of designs incorporating the joint test for the sample size and number of events. We then present a small simulation study of the power of the joint test when nonPH is present. We finish with a discussion and conclusions.
Methods
Motivation
The basic issue that concerns us is that a clinically important treatment effect may be more complex than implied by a simple hazard ratio (HR) between treatment arms. For example, survival curves that diverge then converge or even cross may suggest the mode of action of a research treatment. A simple HR would not do justice to interpreting such data. One might say, ‘just plan the sample size according to the logrank test as usual, then test for nonPH after that’. But if the test of nonPH is positive, how does one proceed  particularly in cases where the logrank test does not exhibit conventional levels of significance and the nonPH test does? It should be noted that the significance level of such a sequential procedure is approximately double the nominal level of the logrank test, since two independent tests have been carried out. Doubling the probability of a type 1 error is not likely to be acceptable to trialists.
An obvious difficulty here is the very general nature of possible departures from PH. This makes it nigh impossible to confidently and convincingly prespecify a timedependent pattern of HR behaviour with which to power the logrank test. We believe it is preferable and practically more appealing to power it under PH, as a rough approximation to what might be expected, but with an adjustment to allow a ‘second degree of freedom’ to incorporate a rather general test of nonPH. For the latter, we suggest the GrambschTherneau test [3] based on the correlation between scaled Schoenfeld residuals and (our preference) the ranks of the failure times.
We assume that the GrambschTherneau test statistic is independent of the Cox or logrank test of the treatment effect and under PH has a central chisquare distribution on 1 degree of freedom (d.f.). (See further comments on this assumption in the next paragraph.) The sum of the logrank or Cox and GrambschTherneau chisquare statistics provides a test statistic whose distribution under the global null hypothesis of identical survival functions across treatment arms is central chisquare on 2 d.f.
To check the above assumptions, we ran some simple simulations which we do not report in detail. In essence, with sets of 5,000 replicated twoarm ‘trials’ with staggered patient entry, we found that, in the null case, the GrambschTherneau test statistic was very close to χ^{2} on 1 d.f. and the joint test statistic was very close to χ^{2} on 2 d.f. The Spearman rank correlation between the two component test statistics was close to zero. We conclude that the assumptions are sound.
A joint test
 1.
To widen the concept of ‘treatment effect’ to include the important possibility that the HR may depend on time since randomization, and in some cases, the estimated HR is ‘not significant’;
 2.
To have planned power to detect a treatment effect (in terms of the HR) of prespecified magnitude under PH;
 3.
To have power in cases of nonPH in which the power of the logrank test alone could be compromised.
Our suggested joint test is as described above. Of course, other choices are possible, notably, based on a flexible parametric survival model with a timedependent treatment effect [4, 5]. We comment further on this issue in the Discussion.
Power
We now consider the implications for sample size and power of replacing the logrank test with a joint test as just described. Suppose that there is a nonnull treatment effect (HR ≠1) and PH holds. In such cases, the second component of the joint test is null, but not the first. By applying the joint test under PH, we ‘waste’ one d.f., reducing the power compared with the more parsimonious and (under PH) universally most powerful logrank test. Since the logrank test is asymptotically equivalent to a Cox test, we can equally well substitute the likelihood ratio or Wald chisquare statistic from Cox regression on the treatment indicator variable for the logrank chisquare statistic.
where F_{ ν }(λ,u) is the distribution function of a noncentral χ^{2} variate u with ν d.f. and noncentrality parameter λ, and ${C}_{\nu}^{1}\left(p\right)$ is the central chisquare deviate on ν d.f. corresponding to probability p. For example, ${C}_{2}^{1}\left(0.95\right)\simeq 5.99$. The required functions are widely available in software packages. In Stata, for instance, F_{ ν }(λ,u) and ${C}_{\nu}^{1}\left(p\right)$ are implemented as functions nchi2( ν,λ,u ) and invchi2( ν,p), respectively.
We describe our preferred approach to powering the joint test in the Discussion. First, we describe three possible strategies.
Strategy 1: Power the logrank test as usual
This is the simplest approach. We power the logrank test as usual and use Equation (1) to calculate the resulting joint test power, ω_{ J T }. For example, with significance level α=0.05 and power ω=(0.8,0.9) we find ω_{ J T }=(0.709,0.835). Many people would probably be happy with (ω,ω_{ J T })=(0.9,0.835), whereas they might find ω_{ J T }=0.709 too low for comfort.
Strategy 2: Power the joint test
We might prefer to specify a power ω_{ J T } for the joint test at significance level α under PH. What corresponding value of ω is needed for the logrank test?
where G_{ ν }(u,p) is the noncentrality parameter of a noncentral χ^{2} variate with ν d.f. at a value p of the distribution function. If F_{ ν }(λ,u)=p, then G_{ ν }(u,p)=λ. In Stata, G_{ ν }(u,p) is implemented as function npnchi2( ν,u,p ).
For example, suppose we require ω_{ J T }=0.8 at α=0.05. According to Equation (2) we find that ${G}_{2}\left[{C}_{2}^{1}\left(1\alpha \right),1{\omega}_{\mathit{\text{JT}}}\right]=9.63469$, ${\omega}_{\mathit{\text{LR}}}=\Phi \left(\sqrt{9.63469}1.95996\right)=0.87369$. The study would therefore need power 0.874 for the logrank test under PH, with a corresponding increase in sample size.
Strategy 3: Relax the significance level of the joint test
where, for instance, ${F}_{\nu}^{1}\left(\lambda ,p\right)$ is implemented in Stata as invnchi2( ν,λ,p ). For example, with α=0.05, ω=0.9 we find α_{ J T }=0.0985 (that is, nearly 2α). With α=0.05, ω=0.8, then α_{ J T }=0.0952. Taking α_{ J T }≃2α is likely to be adequate in practice for 0.8≤ω≤0.95. In most trials, power is set at 0.8 or 0.9.
Presentation of results
Traditionally, studies with a timetoevent outcome are designed according to a target HR and reported with an estimate of the resulting HR and a 95% confidence interval, usually obtained from a Cox regression as already mentioned. The HR may or may not be adjusted for covariates such as important prognostic factors or stratifying variables. Often, a graph of the KaplanMeier estimates of the survival curves is presented.
In the emerging era in which the PH assumption may fail [6, 7] (for reasons we could speculate about), the traditional strategy seems inadequate. We have argued [2] for estimating and presenting alternative measures of a treatment effect which do not rely on a timeindependent HR. Here we suggest producing two closely related reports: graphical and quantitative.
Graphical presentation
The key understanding is that most measures of clinical and statistical relevance in the nonPH context are timedependent. These include, obviously, the traditional survival functions, but also the HR, the difference in restricted mean survival time between treatments [2], and the difference in survival functions between treatments. We propose presenting plots of all four of these quantities against time in a single graphic image.
Restricted mean survival time (RMST) for a mortality outcome in a trial may loosely be described as the life expectancy over the restricted period between randomization and a defined, clinically relevant time horizon, usually called t^{∗}. With uncensored survival times t_{1},…,t_{ n } we would first ‘truncate’ values that exceed t^{∗} by setting ${t}_{i}^{{}^{\prime}}=max\left({t}_{i},{t}^{\ast}\right)$ Then RMST =$\frac{1}{n}\sum _{i=1}^{n}{t}_{i}^{{}^{\prime}}$ is the usual definition of a mean applied to the truncated survival times. With right censoring, an alternative formula is needed, namely RMST =$\underset{0}{\overset{{t}^{\ast}}{\int}}S\left(t\right)\mathit{\text{dt}}$, where S(t) is an estimate of the survival function for the n patients [8].
Figure 1(c) indicates that the treatment effect on the relative hazard scale is largest near t=0 and dwindles to HR =1 by about t=4 yr. The survival curves do not cross within the interval (0,8) yr, so the RMST difference, which is the integrated difference between the survival curves, increases in a monotone fashion. By t=8 yr it reaches about 0.8 yr, albeit with a wide confidence interval.
Quantitative results
We propose that the primary quantitative estimates are taken as the overall HR with its confidence interval (noting that the instantaneous HR may be timedependent) and the difference(s) in restricted mean survival time, with confidence interval(s).
The report of quantitative results should include the Pvalues from each of the three tests (the joint test and its two components), the joint test being the primary comparison and the two components as supporting evidence. The HR from a Cox model and results from Figure 1 at one to three clinically relevant timepoint(s) should also be reported.
Overall hazard ratio and test statistics for the GOG111 and PATCH trials
Trial  Hazard ratio  Joint test  Cox test of HR = 1  GT test of PH  

Est.  95% CI  Chisq.  P  Chisq.  P  Chisq.  P  
GOG111  0.73  (0.59,0.90)  15.90  0.0004  8.38  0.0038  7.52  0.0061 
PATCH1  0.71  (0.50,1.00)  7.58  0.023  3.78  0.052  3.80  0.051 
Timedependent quantitative results for the GOG111 trial
Quantity  t=2 yr  t=5 yr  

Est.  95% CI  Est.  95% CI  
HR (t)  0.71  (0.57,0.89)  0.99  (0.71,1.39) 
S_{0}(t)  0.52  (0.46,0.58)  0.18  (0.13,0.23) 
S_{1}(t)  0.68  (0.62,0.73)  0.27  (0.22,0.33) 
S_{1}(t)S_{0}(t)  0.16  (0.07,0.24)  0.09  (0.02,0.16) 
RMST _{0} (yr)  1.53  (1.45,1.61)  2.44  (2.22,2.67) 
RMST _{1} (yr)  1.73  (1.66,1.79)  3.04  (2.81,3.26) 
RMST _{1} RMST _{0}  0.20  (0.09,0.30)  0.59  (0.27,0.91) 
A second example
PATCH1 is a randomized, doubleblind trial comparing a 12month course of lowdose penicillin with a placebo in the prevention of recurrent cellulitis of the leg, a common baterial infection of the skin and underlying tissue [10]. The trial is rather small, with 129 events (patients experiencing one or more recurrences) among 274 patients followed up for a maximum of 3 years.
The results here are particularly intriguing. Neither of the individual treatmenteffect tests are formally significant at the 5% level, although both are very close to significant (see Table 1). In contrast, the joint test has a Pvalue of 0.02. The conclusions from the trial analysis could hinge on which approach to testing was taken. Figure 2(c) shows that, as with GOG111, the treatmenteffect HR appears substantial near t=0 and diminishes rapidly over the course of followup, being near 1 after 1 year. Note the generally large uncertainty in the estimates.
Estimation
Model for a timedependent treatment effect
In the preceding section, we have recommended a particular presentation of results without indicating how the results were obtained. Obviously, the KaplanMeier curves in Figure 1(a) and the hazard ratio estimate and tests in Table 1 are standard and familiar. This cannot be said of the other graphs and corresponding quantities in Table 2.
There are many ways in which the curves in Figure 1 could have been estimated. None can be said to be ‘standard’. Figure 1 was actually produced using a timedependent, hazardsscaled flexible parametric survival model (FPM) [4, 5]. This is the model class we propose and focus on.
The function θ(t)=θ_{0}+θ_{1} ln(t) describes the timedependent behaviour of the ratio of log cumulative hazard functions between trial arms as a linear function of log time. This choice is similar to, but differs slightly from, Cox’s suggestion [11] for modelling a timedependent hazard ratio. In the latter, the log hazard function is modelled as lnh(t;x)= lnh_{0}(t)+θ(t)x= lnh_{0}(t)+[θ_{0}+θ_{1}f(t)]x, where f(t) is some simple parametric function of time such as lnt or $\sqrt{t}$.
When θ(t) is constant, that is, when θ_{1}=0, the cumulative hazards and hence also the hazards in the FPM are proportional between treatment groups. Equation (3) is then a PH model with HR equal to exp(θ_{0}).
Predefining the statistical analysis
These days, randomized controlled trials are heavily regulated in various ways. One requirement is for a detailed statistical analysis plan to be drawn up before the trial data are finalized and analysed. The plan should lay out how the data will be analysed. The aim is to avoid any temptation on the part of the investigators to interpret the data overoptimistically by a datadriven selection of techniques and their results. In our context, we need to prespecify the significance tests(s) that will be applied to gauge the evidence for a nonnull treatment effect, and the model(s) that will be fitted to the data, from which key estimates will be derived.
The joint test is straightforward to specify since it requires the logrank or Cox chisquare value and the GrambschTherneau chisquare statistic using, for example, the rank transformation of the failure times. (Other time transformations are sometimes used, but no evidence that we are aware of favours any particular one.) The primary test of the treatment effect is then the sum of the two chisquares, which is tested on 2 d.f. at the appropriate significance level. The overall HR estimate and its confidence interval are taken from the Cox regression.
Regarding the choice of FPM, we remarked that ‘a sensible default strategy … is to assign 3 d.f. to the baseline distribution and 1 d.f. to a timedependent treatment effect to account for possible nonPH’ [2]. Further experience since that publication has confirmed that this model specification is flexible enough to fit the vast majority of trials we have encountered. In our approach, 3 d.f. means that the baseline s_{0}(lnt) is a restricted cubic spline function with a boundary knot at each of the extreme failure times and interior knots at the 33rd and 67th centiles of the failure times. The baseline function is required in the estimation of the survival and other curves shown in Figures 1 and 2.
We have occasionally encountered trials in which the timedependent component, θ_{1} ln(t), of the treatment effect is more complex than a logarithmic function of time. Such additional complexity could be investigated in secondary analyses. However, we judge that the simplicity and particularly the parsimony of model (3) are essential to a robust, prespecified primary analysis. Similarly, 3 d.f. for the baseline spline may occasionally seem insufficient according to, say, an information criterion. Nevertheless, the improvement in fit to survival probabilities when further knots are included is typically small and of little practical importance. See also Royston and Lambert [5] pp. 7479.
Results
Simulation study
We performed a small simulation study of the power of the joint test under nonPH. (The power under PH is known.) We powered a hypothetical trial design under the logrank test with a sufficient sample size and number of events for the joint test to have power 0.8 under PH, at a twosided significance level of 0.05. The corresponding power of the logrank test under PH was 0.874. The target HR was taken to be 0.75. We assumed staggered entry of patients into the ‘trial’ at a uniform rate for 8 years, with a subsequent followup period of 4 years. Thus, the minimum and maximum possible followup times for any patient were 4 and 12 years, respectively. The required numbers of patients and events were 700 and 467, respectively.
Design parameters for the simulation study of power
Time,t  S_{0}( t)  HR_{1}( t)  HR_{2}( t)  Time,t  S_{0}( t)  HR_{1}( t)  HR_{2}( t) 

1  0.767  1.00  0.65  7  0.302  0.60  1.0 
2  0.628  0.85  0.70  8  0.268  0.60  1.0 
3  0.529  0.70  0.75  9  0.238  0.60  1.1 
4  0.453  0.65  0.80  10  0.213  0.60  1.1 
5  0.392  0.60  0.90  11  0.191  0.60  1.2 
6  0.343  0.60  0.90  12  0.172  0.60  1.2 
Power of tests under different scenarios: simulation results
Test  Treatment effect  

Constant (PH)^{ a }  Increasing (HR_{1})^{ b }  Decreasing (HR_{2})^{ c }  
Logrank  0.874  0.719 (0.006)  0.820 (0.005) 
Joint  0.800  0.854 (0.005)  0.855 (0.005) 
Numerical examples of sample size
Example of sample size calculation for the joint test under PH
Power of test under PH  Target HR  Sample size  

Logrank  Joint  n  events  
0.8  0.709  0.70  378  248 
0.75  570  380  
0.80  931  632  
0.9  0.835  0.70  506  332 
0.75  763  509  
0.80  1246  845  
0.874  0.8  0.70  464  304 
0.75  700  467  
0.80  1142  775  
0.945  0.9  0.70  610  399 
0.75  919  613  
0.80  1500  1018 
In general, about 20 percent more events are required by the joint test than the logrank test. For example, for target HR =0.75, the joint test with power 0.9 requires logrank power 0.945 and 20.4 percent more patients and events than the logrank test with power 0.9 (919 versus 763 patients, 613 versus 509 events).
Discussion
Our paper has two components: trial design with associated significance testing, and estimation of results. We discuss these briefly in turn.
There is no particular reason that we are aware of for expecting proportional hazards of the treatment effect. It is a convenient assumption that facilitates sample size calculation in timetoevent data. Our basic design idea is to improve the power to detect a more general, that is, potentially more complex, treatment effect than PH. The motivation is the increasingly frequent occurrence of nonPH in trials, with a concern that the power of the logrank test may be low in some of these cases. The outcome could be a trial declared or regarded as ‘negative’, when in fact a clinically relevant difference in survival curves between treatments was present.
There are costs to generalizing the concept of a treatment effect. Patterns of nonPH are potentially very varied, and it is hard, if not impossible, to design a trial with a convincing prior assumption about the likely pattern. Our proposed solution is to power the trial under PH according to a twopart (‘joint’) test. By combining the usual logrank or Cox test with the GrambschTherneau test of nonPH, we incur a loss of power under PH, but we may gain power under nonPH.
We discussed three possible strategies for trial design: (1) power according to the logrank test, with a hit in power of the joint test; (2) power according to the joint test, with an increase in sample size required via the higher power used in the logrank test; or (3) the same strategy as (2), but relaxing the significance level of the joint test to achieve the same power as the logrank test.
We have a slight preference for strategy 2. A frequent choice, for example, in past Medical Research Council (MRC) cancer trials has been to power the logrank test at 90 percent with significance level 5 percent and a target HR of 0.75. As we have seen, such a design guarantees power of 83.5 percent for the joint test under PH, which many would consider adequate. Others may have different preferences. We indicate how to do the relatively straightforward power calculations in the present paper. Sophisticated methodology and software (for example, [12, 13]) are available for implementing complex trial designs under the logrank test. These can of course also be used with the joint test under PH.
The GrambschTherneau test is based on scaled Schoenfeld residuals derived from a Cox PH model. Schoenfeld residuals are unsuitable for estimation of the quantities of substantive interest in a survival analysis of trial data. For that reason, for estimation, we suggest using a flexible parametric model with a timedependent treatment effect. This class of models can be prespecified in sufficient detail in a protocol and statistical analysis plan. It provides smooth estimates of survival probabilities, hazard ratio functions, restricted mean survival times, and so on. While there is a potential risk of bias due to the FPM failing to fit the data adequately, our experience so far is that noticeable lack of fit to the survival functions is uncommon. Of course, the Cox model can also fit badly.
The timedependent treatment effect function incorporated in the FPM is loglinear in the followup time and therefore of limited flexibility. The fit can be checked by inspecting a plot of smoothed Schoenfeld residuals against the failure times, which gives a ‘nonparametric’ impression of the pattern of the log hazard ratio over time. If necessary, in secondary analysis the FPM can be elaborated with further spline parameters to improve the fit.
A sensible alternative to the joint test we describe is a joint test of the two parameters θ_{0} and θ_{1} in the FPM. This test, also on 2 d.f., is of the treatment effect and its interaction with (log) time. The global null hypothesis is θ_{0}=θ_{1}=0 (see Equation (3)). In an informal comparison using a database of 25 heterogeneous RCTs, we found good agreement and no consistent differences in the Pvalues of the two joint tests (data not shown). At this point, we have no empirical evidence to support recommending one test over the other. However, one theoretical consideration favouring the Cox/GrambschTherneau joint test is that the GrambschTherneau test is more general than the timedependent function θ_{0}+θ_{1} lnt. It is conceivable, therefore, that the Cox/GrambschTherneau test may tend to have higher power in general than the FPMbased joint test. On the other hand, some researchers may favour congruence between the global test for a treatment effect being based on the FPM and the same FPM being used in the description and interpretation of the trial results.
A key feature of the joint test is that it is sensitive to simple and also to more ‘complex’ treatment effects. In the latter case, assuming the result is not a type 1 error, the test is indicating there is a genuine difference between the survival curves. Even if the overall treatment effect, considered over the entire followup time of the trial, is small, the difference between the arms may still be of clinical and/or scientific interest and importance. For example, the difference in the survival curves between the treatment arms may suggest possible mechanisms of action of the treatments.
We are not suggesting that the joint test be adopted routinely. Primarily, we suggest that the trialist choose the preferred test according to the perceived modes of action of the treatments being compared. If the modes are obviously different, for example surgery versus a more conservative approach such as watchful waiting or a nonsurgical therapy, the hazard functions will probably differ markedly in shape and nonPH seems more likely. The joint test may then be a good choice. If rather similar treatments are involved, such as various chemotherapy regimens, nonPH may seem less likely and the logrank test may be best. There may be indications of the extent and nature of nonPH from earlier trials or, in cancer for example, from other cancer types in which the treatment has been evaluated. Another consideration is judging how close to PH the ensuing survival curves are likely to be. If a treatment effect is expected to emerge relatively soon after randomization, nonPH is likely to be mild and the logrank test will be the more powerful. If the effect emerges much later in followup, the joint test is likely to be more powerful.
Conclusion
The design and analysis of trials in the era of nonproportional hazards needs to accommodate a wider consideration of the nature of treatment effects. We have suggested one way forward which retains the tools familiar in the standard approach to trial design and sample size under proportional hazards, but which utilizes a joint test of the null hypothesis with power against nonproportional hazards. The trialist can choose whether to pay the price of the generalization by increasing the sample size or relaxing the significance level used in the joint test. We recommend the former. For analysis of the trial data, our approach prespecifies a flexible parametric model that can represent a timedependent hazard ratio if one is present.
Authors’ information
Both authors are biostatisticians. MKBP is the director of the MRC Clinical Trials Unit at UCL. PR is a senior statistician in the same unit and an honorary professor of statistics at UCL.
Abbreviations
 CI:

confidence interval
 d.f.:

degrees of freedom
 FPM:

flexible parametric model
 HR:

hazard ratio
 MRC:

Medical Research Council
 nonPH:

nonproportional hazards
 PH:

proportional hazards
 RCT:

randomized controlled trial
 RMST:

restricted mean survival time.
Declarations
Acknowledgements
We thank the Gynecologic Oncology Group for permission to use updated individual patient data from the GOG111 trial as an example. We are gratefu to two reviewers whose comments helped us to improve the manuscript.
Authors’ Affiliations
References
 Schemper M, Wakounig S, Heinze G:The estimation of average hazard ratios by weighted Cox regression. Stat Med. 2009, 28: 24732489. 10.1002/sim.3623.View ArticlePubMed
 Royston P, Parmar MKB:The use of restricted mean survival time to estimate the treatment effect in randomized clinical trials when the proportional hazards assumption is in doubt. Stat Med. 2011, 30: 24092421. 10.1002/sim.4274.View ArticlePubMed
 Grambsch PM, Therneau TM:Proportional hazards tests and diagnostics based on weighted residuals. Biometrika. 1994, 81: 515526. 10.1093/biomet/81.3.515.View Article
 Royston P, Parmar MKB:Flexible proportionalhazards and proportionalodds models for censored survival data, with application to prognostic modelling and estimation of treatment effects. Stat Med. 2002, 21: 21752197. 10.1002/sim.1203.View ArticlePubMed
 Royston P, Lambert PC: Flexible parametric survival analysis using Stata: beyond the Cox model. 2011, College Station, Tx: Stata Press
 Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, Nishiwaki Y, Ohe Y, Yang JJ, Chewaskulyong B, Jiang H, Duffield EL, Watkins CL, Armour AA, Fukuoka M:Gefitinib or carboplatinpaclitaxel in pulmonary adenocarcinoma. New Engl J Med. 2009, 361: 947957. 10.1056/NEJMoa0810699.View ArticlePubMed
 Stark D, Nankivell M, PujadeLauraine E, Kristensen G, Elit L, Stockler M, Hilpert F, Cervantes A, Brown J, Lanceley A, Velikova G, Sabate E, Pfisterer J, Carey MS, Beale P, Qian W, Swart AM, Oza A, Perren T:Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: qualityoflife outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase 3 randomised trial. Lancet Oncol. 2013, 14: 236243. 10.1016/S14702045(12)705673.PubMed CentralView ArticlePubMed
 Andersen PK, Hansen MG, Klein JP:Regression analysis of restricted mean survival time based on pseudoobservations. Lifetime Data Anal. 2005, 10: 335350.View Article
 McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, ClarkePearson DL, Davidson M:Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. New Engl J Med. 1996, 334: 16. 10.1056/NEJM199601043340101.View ArticlePubMed
 Thomas KS, others for the PATCH1 Trial Team:Penicillin to prevent recurrent leg cellulitis. New Engl J Med. 2013, 368: 16951703. 10.1056/NEJMoa1206300.View ArticlePubMed
 Cox DR:Regression models and lifetables (with discussion). J R Stat Soc (Series B). 1972, 34: 187220.
 Barthel FMS, Royston P, Babiker A:A menudriven facility for complex sample size calculation in randomized controlled trials with a survival or a binary outcome: update. Stat J. 2005, 5: 123129.
 Barthel FMS, Babiker A, Royston P, Parmar MKB:Evaluation of sample size and power for multiarm survival trials allowing for nonuniform accrual, nonproportional hazards, loss to followup and crossover. Stat Med. 2006, 25: 25212542. 10.1002/sim.2517.View ArticlePubMed
Copyright
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.